Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?

Targeted Oncology

Volumn 9, Issue 2, 2014, Pages 171-175

  Koçer, Nazim Emrah ^a   Kayaselçuk, Fazilet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Anti EGFR therapy; Colorectal carcinoma; Fascin; K RAS

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FASCIN; K RAS PROTEIN; ACTIN BINDING PROTEIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CETUXIMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FSCN1 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PANITUMUMAB; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CODON; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; YOUNG ADULT; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84902547698     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0275-8     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 http://globocan.iarc.fr/factsheet.asp Accessed 03 April 2012
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2012) SEER Cancer statistics review, 1975-2009 http://seer.cancer.gov/statfacts/html/colorect.html Accessed 25 August 2012
3. Hashimoto Y, Kim DJ, Adams JC (2011) The roles of fascins in health and disease. J Pathol 224(3):289-300
4. Hashimoto Y, Skacel M, Lavery IC et al (2006) Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 6:241
5. Oh SY, Kim YB, Suh KW et al (2012) Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer. J Surg Res 172(1):102-108
6. Puppa G, Maisonneuve P, Sonzogni A et al (2007) Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer 96(7):1118-1126 (Pubitemid 46608324)
7. El Zouhairi M, Charabaty A, Pishvaian MJ (2011) Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 4(1):15-21
8. van Krieken JH, Jung A, Kirchner T et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453(5):417-431
9. Heinemann V, Stintzing S, Kirchner T (2009) Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 35(3):262-271
10. Chan C, Jankova L, Fung CL et al (2010) Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. Am J Surg Pathol 34(5):656-666
11. Kureishy N, Sapountzi V, Prag S et al (2002) Fascins and their roles in cell structure and function. Bioessays 24(4):350-361 (Pubitemid 34305690)
12. Jawhari AU, Buda A, Jenkins M et al (2003) Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162(1):69-80 (Pubitemid 36041990)
13. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14):2787-2799 (Pubitemid 46606324)
14. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23(11):2445-2459 (Pubitemid 47050835)
15. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341- 354
16. Neumann J, Zeindl-Eberhart E, Kirchner T et al (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205(12):858-862
17. Andreyev HJ, Norman AR, Cunningham D et al (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90(9):675-684 (Pubitemid 28222141)
18. Dix BR, Robbins P, Soong R et al (1994) The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59(6):747-751
19. Russo A, Bazan V, Agnese V et al (2005) Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16(Suppl 4):iv44-iv49 (Pubitemid 43084945)
20. Tortola S, Marcuello E, González I et al (1999) p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17(5):1375-1381 (Pubitemid 29220842)
21. Esteller M, González S, Risques RA et al (2001) K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19(2):299-304 (Pubitemid 32112840)
22. Modest DP, Stintzing S, Laubender RP et al (2011) Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 22(9):913-918
23. Bouzourene H, Gervaz P, Cerottini JP et al (2000) p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36(8):1008-1015 (Pubitemid 30316426)
24. Hurwitz HI, Yi J, Ince W et al (2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14(1):22-28
25. Petrowsky H, Sturm I, Graubitz O et al (2001) Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 27(1):80-87 (Pubitemid 32229699)